Destiny Pharma (LSE:DEST) Total Current Assets : £7.60 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Destiny Pharma's total current assets for the quarter that ended in Dec. 2023 was £7.60 Mil.

Destiny Pharma Total Current Assets Historical Data

The historical data trend for Destiny Pharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma Total Current Assets Chart

Destiny Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

8.53

11.43

5.99

6.51

7.60

Destiny Pharma Semi-Annual Data
	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Current Assets	Get a 7-Day Free Trial												5.99	9.21	6.51	10.68	7.60

Destiny Pharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Destiny Pharma's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6.383	+	0.111	+	0	+	1.103
	=	7.60

Destiny Pharma's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6.383	+	0.111	+	0	+	1.103
	=	7.60

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Destiny Pharma (LSE:DEST) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Destiny Pharma's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.383	-	0.768	+	0.75 * 0	+	0.5 * 0
=	5.62

Destiny Pharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of Destiny Pharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Destiny Pharma (LSE:DEST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

D89:Germany

Address

Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB

Website

https://www.destinypharma.com

Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines